BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Receives $390.92 Consensus PT from Analysts

Shares of BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) have been given a consensus recommendation of “Moderate Buy” by the fifteen brokerages that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $390.9231.

ONC has been the topic of a number of analyst reports. Wells Fargo & Company began coverage on shares of BeOne Medicines in a report on Monday, May 4th. They issued an “overweight” rating and a $400.00 target price on the stock. Guggenheim lifted their price target on BeOne Medicines from $410.00 to $420.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Wall Street Zen raised BeOne Medicines from a “buy” rating to a “strong-buy” rating in a report on Saturday, July 18th. Leerink Partners increased their price objective on BeOne Medicines from $364.00 to $367.00 and gave the stock an “outperform” rating in a research note on Friday, May 15th. Finally, Zacks Research lowered BeOne Medicines from a “strong-buy” rating to a “hold” rating in a report on Friday, July 3rd.

BeOne Medicines Stock Performance

Shares of ONC stock opened at $319.93 on Friday. The firm has a market capitalization of $35.10 billion, a PE ratio of 71.57 and a beta of 0.49. The firm has a fifty day simple moving average of $290.35 and a two-hundred day simple moving average of $309.20. The company has a current ratio of 3.64, a quick ratio of 3.27 and a debt-to-equity ratio of 0.20. BeOne Medicines has a 12 month low of $253.95 and a 12 month high of $385.22.

BeOne Medicines (NASDAQ:ONC) last released its quarterly earnings data on Wednesday, April 1st. The company reported $0.25 earnings per share for the quarter. The firm had revenue of $1.51 billion for the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. Analysts forecast that BeOne Medicines will post 5.86 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO John Oyler sold 145,861 shares of the company’s stock in a transaction on Tuesday, July 14th. The shares were sold at an average price of $305.95, for a total value of $44,626,172.95. Following the completion of the sale, the chief executive officer owned 8,122 shares in the company, valued at $2,484,925.90. This represents a 94.73% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Xiaobin Wu sold 1,292 shares of the stock in a transaction dated Tuesday, June 23rd. The shares were sold at an average price of $276.26, for a total transaction of $356,927.92. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 233,647 shares of company stock valued at $70,335,553. 6.19% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On BeOne Medicines

A number of institutional investors have recently added to or reduced their stakes in the company. Generali Investments Management Co LLC purchased a new stake in BeOne Medicines in the 2nd quarter valued at about $2,280,000. Charles Schwab Trust Co bought a new position in shares of BeOne Medicines during the 2nd quarter worth approximately $855,000. Steadtrust LLC boosted its stake in shares of BeOne Medicines by 3.7% in the 2nd quarter. Steadtrust LLC now owns 1,400 shares of the company’s stock worth $399,000 after buying an additional 50 shares during the last quarter. Empowered Funds LLC purchased a new position in shares of BeOne Medicines in the 1st quarter worth approximately $201,000. Finally, Bank of America Corp DE grew its holdings in shares of BeOne Medicines by 7.0% in the first quarter. Bank of America Corp DE now owns 405,273 shares of the company’s stock valued at $120,354,000 after acquiring an additional 26,441 shares in the last quarter. 48.55% of the stock is owned by institutional investors.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.